|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. Feb 4–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dahan L, Sadok A, Formento JL, Seitz JF
and Kovacic H: Modulation of cellular redox state underlies
antagonism between oxaliplatin and cetuximab in human colorectal
cancer cell lines. Br J Pharmacol. 158:610–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bleiberg H: Oxaliplatin (L-OHP): a new
reality in colorectal cancer. Brit J Cancer. (Suppl 4). 1–3. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alcindor T and Beauger N: Oxaliplatin: a
review in the era of molecularly targeted therapy. Curr Oncol.
18:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Howells LM, Sale S, Sriramareddy SN, et
al: Curcumin ameliorates oxaliplatin-induced chemoresistance in
HCT116 colorectal cancer cells in vitro and in vivo. Int J Cancer.
129:476–486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Klionsky DJ and Emr SD: Autophagy as a
regulated pathway of cellular degradation. Science. 290:1717–1721.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
White E: Deconvoluting the
context-dependent role for autophagy in cancer. Nat Rev Cancer.
12:401–410. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: an evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen S, Rehman SK, Zhang W, Wen A, Yao L
and Zhang J: Autophagy is a therapeutic target in anticancer drug
resistance. Biochim Biophys Acta. 1806:220–229. 2010.PubMed/NCBI
|
|
11
|
Bijnsdorp IV, Peters GJ, Temmink OH,
Fukushima M and Kruyt FA: Differential activation of cell death and
autophagy results in an increased cytotoxic potential for
trifluorothymidine compared to 5-fluorouracil in colon cancer
cells. Int J Cancer. 126:2457–2468. 2010.PubMed/NCBI
|
|
12
|
Li J, Hou N, Faried A, Tsutsumi S,
Takeuchi T and Kuwano H: Inhibition of autophagy by 3-MA enhances
the effect of 5-FU-induced apoptosis in colon cancer cells. Ann
Surg Oncol. 16:761–771. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi Y, Tang B, Yu PW, et al: Autophagy
protects against oxaliplatin-induced cell death via ER stress and
ROS in Caco-2 cells. PloS One. 7:e510762012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu Y, Yu H, Qin H, et al: Inhibition of
autophagy enhances cisplatin cytotoxicity through endoplasmic
reticulum stress in human cervical cancer cells. Cancer Lett.
314:232–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sasaki K, Tsuno NH, Sunami E, et al:
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on
colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi W, Tang Q, Chen X, et al: Antitumor
and antimetastatic activities of vesicular stomatitis virus matrix
protein in a murine model of breast cancer. J Mol Med (Berl).
87:493–506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amaravadi RK, Yu D, Lum JJ, et al:
Autophagy inhibition enhances therapy-induced apoptosis in a
Myc-induced model of lymphoma. J Clin Invest. 117:326–336. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Romano S, D'Angelillo A, Pacelli R, et al:
Role of FK506-binding protein 51 in the control of apoptosis of
irradiated melanoma cells. Cell Death Differ. 17:145–157. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.PubMed/NCBI
|
|
20
|
André T, Boni C, Navarro M, et al:
Improved overall survival with oxaliplatin, fluorouracil and
leucovorin as adjuvant treatment in stage II or III colon cancer in
the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuebler JP, Wieand HS, O'Connell MJ, et
al: Oxaliplatin combined with weekly bolus fluorouracil and
leucovorin as surgical adjuvant chemotherapy for stage II and III
colon cancer: results from NSABP C-07. J Clin Oncol. 25:2198–2204.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He G, Wang Y, Pang X and Zhang B:
Inhibition of autophagy induced by TSA sensitizes colon cancer cell
to radiation. Tumour Biol. 35:1003–1011. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giatromanolaki A, Koukourakis MI, Harris
AL, Polychronidis A, Gatter KC and Sivridis E: Prognostic relevance
of light chain 3 (LC3A) autophagy patterns in colorectal
adenocarcinomas. J Clin Pathol. 63:867–872. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giatromanolaki A, Koukourakis MI,
Koutsopoulos AV, Harris AL, Gatter KC and Sivridis E: Autophagy and
hypoxia in colonic adenomas related to aggressive features.
Colorectal Dis. 15:e223–e230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koukourakis MI, Giatromanolaki A, Sivridis
E, Pitiakoudis M, Gatter KC and Harris AL: Beclin 1 over- and
underexpression in colorectal cancer: distinct patterns relate to
prognosis and tumour hypoxia. Brit J Cancer. 103:1209–1214. 2010.
View Article : Google Scholar : PubMed/NCBI
|
